LOGIN  |  REGISTER
Assertio
C4 Therapeutics

BrightSpring Health Services to Announce Fourth Quarter and Full Year 2023 Financial Results and Hold Investor Conference Call on February 29, 2024

February 15, 2024 | Last Trade: US$23.60 0.64 -2.64

LOUISVILLE, Ky., Feb. 15, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.

Conference Call Details

To participate in the conference call, please register here before the 8:30 a.m. ET start. The call will also be webcast live on the Company’s investor relations website at https://ir.brightspringhealth.com under the “Events & Presentations” section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here.

Following the conference call, a replay of the webcast will be available on the Company’s investor relations website, https://ir.brightspringhealth.com/.

About BrightSpring Health Services

BrightSpring Health Services is the parent company of leading healthcare service lines that provide complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the company’s high-quality and impactful pharmacy, primary care and home health care, and rehabilitation and behavioral health services, and through its skilled and dedicated employees, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. For more information, visit www.brightspringhealth.com.

Contact

Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it. 
502.630.7412

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page